
Kingfa Science (KINGFA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
4.7B
Gross Profit
1.1B
22.70%
Operating Income
905.7M
19.29%
Net Income
419.0M
8.92%
Balance Sheet Metrics
Total Assets
11.6B
Total Liabilities
4.3B
Shareholders Equity
7.3B
Debt to Equity
0.59
Cash Flow Metrics
Revenue & Profitability Trend
Kingfa Science Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 17.4B | 14.9B | 14.0B | 10.5B | 6.3B |
Cost of Goods Sold | 13.5B | 12.0B | 11.6B | 8.9B | 5.5B |
Gross Profit | 4.0B | 2.8B | 2.4B | 1.5B | 790.3M |
Gross Margin % | 22.8% | 19.1% | 17.3% | 14.7% | 12.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 584.8M | 498.4M | 331.6M | 277.5M |
Other Operating Expenses | - | 58.1M | 72.6M | 46.8M | -4.3M |
Total Operating Expenses | 0 | 642.9M | 571.1M | 378.4M | 273.1M |
Operating Income | 3.4B | 1.7B | 1.5B | 829.1M | 231.3M |
Operating Margin % | 19.3% | 11.5% | 10.6% | 7.9% | 3.7% |
Non-Operating Items | |||||
Interest Income | - | 10.0M | 12.9M | 8.1M | 10.9M |
Interest Expense | 66.6M | 46.0M | 50.1M | 39.5M | 25.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 2.1B | 1.6B | 1.1B | 413.4M | 118.5M |
Income Tax | 532.2M | 416.7M | 281.8M | 107.1M | 65.3M |
Effective Tax Rate % | 25.8% | 25.4% | 25.7% | 25.9% | 55.1% |
Net Income | 1.5B | 1.2B | 814.1M | 306.3M | 53.2M |
Net Margin % | 8.8% | 8.2% | 5.8% | 2.9% | 0.8% |
Key Metrics | |||||
EBITDA | 2.3B | 1.9B | 1.3B | 826.2M | 322.8M |
EPS (Basic) | ₹126.22 | ₹101.17 | ₹67.22 | ₹25.29 | ₹4.39 |
EPS (Diluted) | ₹126.22 | ₹101.17 | ₹67.22 | ₹25.29 | ₹4.39 |
Basic Shares Outstanding | 12110220 | 12111000 | 12111000 | 12111000 | 12111000 |
Diluted Shares Outstanding | 12110220 | 12111000 | 12111000 | 12111000 | 12111000 |
Income Statement Trend
Kingfa Science Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 234.8M | 50.0M | 24.0M | 85.8M | 37.4M |
Short-term Investments | 89.6M | 6.4M | 228.3M | 215.1M | 210.6M |
Accounts Receivable | 4.5B | 4.0B | 3.6B | 2.8B | 2.1B |
Inventory | 3.0B | 2.4B | 2.9B | 2.6B | 1.4B |
Other Current Assets | 744.0M | 5.3M | 13.0M | 11.8M | -1.0K |
Total Current Assets | 8.5B | 7.3B | 7.4B | 6.1B | 4.1B |
Non-Current Assets | |||||
Property, Plant & Equipment | 2.4B | 74.1M | 74.7M | 74.7M | 61.2M |
Goodwill | 30.0K | 71.0K | 46.0K | 94.0K | 202.0K |
Intangible Assets | - | 71.0K | 46.0K | 94.0K | 202.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 22.5M | 32.8M | 67.1M | -1.0K | 2.0K |
Total Non-Current Assets | 3.0B | 2.7B | 2.7B | 2.7B | 2.6B |
Total Assets | 11.6B | 9.9B | 10.1B | 8.8B | 6.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 3.5B | 3.5B | 4.7B | 4.3B | 2.2B |
Short-term Debt | 409.4M | 310.9M | 394.8M | 250.3M | 431.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 37.9M | 35.1M | 45.2M | 8.1M | 1.2M |
Total Current Liabilities | 4.2B | 4.0B | 5.4B | 4.7B | 2.8B |
Non-Current Liabilities | |||||
Long-term Debt | 20.6M | 14.6M | 29.6M | 168.8M | 243.8M |
Deferred Tax Liabilities | 16.7M | 11.9M | 8.0M | 41.5M | 39.0M |
Other Non-Current Liabilities | - | - | 11.2M | 11.3M | -1.0K |
Total Non-Current Liabilities | 48.3M | 37.6M | 49.0M | 245.2M | 325.7M |
Total Liabilities | 4.3B | 4.1B | 5.4B | 5.0B | 3.2B |
Equity | |||||
Common Stock | 121.1M | 121.1M | 121.1M | 121.1M | 121.1M |
Retained Earnings | 4.5B | 3.1B | 1.9B | 1.1B | 803.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 7.3B | 5.9B | 4.7B | 3.8B | 3.5B |
Key Metrics | |||||
Total Debt | 430.0M | 325.5M | 424.3M | 419.1M | 675.1M |
Working Capital | 4.3B | 3.2B | 2.0B | 1.4B | 1.2B |
Balance Sheet Composition
Kingfa Science Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 2.1B | 1.6B | 1.1B | 413.4M | 118.5M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -1.1B | -104.3M | -1.4B | -2.0B | -522.3M |
Operating Cash Flow | 993.8M | 1.6B | -237.5M | -1.5B | -387.6M |
Investing Activities | |||||
Capital Expenditures | -303.1M | -208.7M | -244.8M | -189.0M | -150.6M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | 0 | -8.4M | - | - |
Investment Sales | - | 215.3M | 0 | - | - |
Investing Cash Flow | -303.1M | 4.8M | -253.2M | -189.0M | -150.6M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -120.5M | - | - | - | - |
Debt Issuance | - | - | - | - | 208.2M |
Debt Repayment | - | 0 | -143.8M | -92.4M | - |
Financing Cash Flow | 20.6M | 0 | -287.5M | -92.4M | 208.2M |
Free Cash Flow | 295.9M | -47.8M | 27.0M | 189.3M | -169.7M |
Net Change in Cash | 711.3M | 1.6B | -778.2M | -1.8B | -330.0M |
Cash Flow Trend
Kingfa Science Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
27.68
Price to Book
5.83
Price to Sales
2.37
PEG Ratio
1.12
Profitability Ratios
Profit Margin
8.58%
Operating Margin
11.17%
Return on Equity
20.98%
Return on Assets
13.23%
Financial Health
Current Ratio
2.02
Debt to Equity
5.90
Beta
0.66
Per Share Data
EPS (TTM)
₹126.79
Book Value per Share
₹601.64
Revenue per Share
₹1,478.31
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
kingfa | 42.5B | 27.68 | 5.83 | 20.98% | 8.58% | 5.90 |
Asian Paints | 2.4T | 65.80 | 12.24 | 18.28% | 10.63% | 11.42 |
Pidilite Industries | 1.6T | 71.77 | 16.03 | 20.85% | 16.16% | 4.56 |
Balaji Amines | 49.7B | 32.59 | 2.69 | 7.80% | 11.11% | 0.55 |
Camlin Fine Sciences | 44.0B | 81.82 | 4.88 | 5.71% | -8.34% | 77.88 |
Grauer & Weil | 43.7B | 27.77 | 4.65 | 18.02% | 13.85% | 1.26 |
Financial data is updated regularly. All figures are in the company's reporting currency.